Oral News and Research

RSS

Federal government requests oral arguments in Michigan appeal of health law challenge

In this case, which was brought by a conservative law center, the plaintiff is seeking to overturn a lower court decision that found the health overhaul to be constitutional.

19 Jan 2011

Positive preliminary results from Soligenix's SGX202 in GARS model

Soligenix, Inc., a late-stage biopharmaceutical company, announced today promising preliminary results from a preclinical study of SGX202 in a canine gastrointestinal acute radiation syndrome model.

19 Jan 2011

Positive results from PLX4032 Phase 3 Trial in patients with metastatic melanoma

Plexxikon today announced positive data from an interim analysis of the BRIM3 trial, a large multi-center Phase 3 clinical study of PLX4032 in patients with previously untreated metastatic melanoma with the BRAF mutation. Patients treated with PLX4032 had an improved overall survival compared to patients treated with dacarbazine, the current standard of care.

19 Jan 2011

New findings show reduced vitamin D absorption in patients with quiescent CD

Researchers from Boston University School of Medicine have for the first time shown that reduced vitamin D absorption in patients with quiescent Crohn's disease may be the cause for their increased risk for vitamin D deficiency.

19 Jan 2011

Annual Society for Endocrinology BES conference to take place in UK from 11-14 April 2011

The annual Society for Endocrinology BES conference is taking place in Birmingham, UK from 11-14 April 2011.

18 Jan 2011

PecFent accepted in Scotland for treatment of breakthrough cancer pain

Archimedes Pharma Ltd., a leading international specialty pharma company, today announced the decision by the Scottish Medicines Consortium to accept PecFent for use within NHS Scotland. PecFent is indicated for the treatment of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain.

18 Jan 2011

Minimally invasive technique appears helpful in reanimating lower face after paralysis

A procedure involving only one small incision and no major modifications to bone can be used to transpose a tendon and appears helpful in reanimating the lower face after paralysis, according to a report in the January/February issue of Archives of Facial Plastic Surgery, one of the JAMA/Archives journals.

18 Jan 2011

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Eli Lilly Canada is pleased to announce the Health Canada approval of BYETTATM for the treatment of adults with type 2 diabetes.

18 Jan 2011

New magnetic pill system can serve as drug delivery tool in patients with cancer, diabetes

A new magnetic pill system developed by Brown University researchers could solve the problem by safely holding a pill in place in the intestine wherever it needs to be.

18 Jan 2011

12-HETE enzyme inhibition can prevent ischemic retinopathy: Study

The inhibition or removal of an enzyme may prevent or treat ischemic retinopathy by stalling growth of unwanted vessels in the retina, Medical College of Georgia researchers say.

14 Jan 2011

Adjunctive lacosamide reduces seizures and improves responder rates

Comprehensive analyses of pooled data from three randomized, double-blind, placebo-controlled Phase II/III trials showing the efficacy and tolerability of Vimpat® (lacosamide) C-V for patients with partial-onset seizures, regardless of the type of concomitant AED used, have been published in the drug evaluation journal, CNS Drugs.

13 Jan 2011

PPPI-III conference to focus on fundamental research and industrial application of particulate processing

Over 80% of all pharmaceutical products are in the solid dosage form. Particulate processes therefore abound in the pharmaceutical industry. These include crystallization; drying, granulation, and coating; tablet compaction; fine powder transport, mixing, and blending. These and other particulate processes are used for the large-scale manufacture of tablets and capsules as well as dry powder inhalants for public consumption.

13 Jan 2011

Family physicians often uncomfortable in discussing IUDs with patients

Intrauterine devices (IUDs) for contraception are safe and effective, but only a small fraction of women in the United States use them.

13 Jan 2011

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.

13 Jan 2011

Patients prepared to travel 'dental miles' to register with NHS dentists

It used to be a fear of the dentist that kept us away from the dental chair but today it is more than twice as likely to be the cost of dental care that's holding us back, according to research from Tesco Dental Insurance.

12 Jan 2011

Apixaban drug raises hope for DVT prevention in patients undergoing hip replacement surgery

A worldwide research consortium that includes the University of Oklahoma Health Sciences Center has proven that a new drug is more effective and easier to use than current medicines in the prevention of blood clots following hip replacement surgery.

12 Jan 2011

Eli Lilly, Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

Boehringer Ingelheim and Eli Lilly and Company today announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development.

12 Jan 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

Rib-X raises $20M to support development of broad spectrum antibiotics pipeline

Rib-X Pharmaceuticals, Inc. today announced that the Company has raised $20 million to support ongoing development of the Company's industry-leading broad spectrum antibiotics pipeline, including late-stage clinical development of delafloxacin, which is expected to enter a Phase 2b study in early 2011.

11 Jan 2011

SciClone initiates phase 2b study of SCV-O7 for oral mucositis

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of the first patient in the company's phase 2b clinical trial of SCV-07 for the prevention of oral mucositis (OM) -- a painful, debilitating, and costly toxicity caused by chemoradiotherapy regimens used to treat head and neck cancer.

11 Jan 2011

Oral News and Research

Federal government requests oral arguments in Michigan appeal of health law challenge

Positive preliminary results from Soligenix's SGX202 in GARS model

Positive results from PLX4032 Phase 3 Trial in patients with metastatic melanoma

New findings show reduced vitamin D absorption in patients with quiescent CD

Annual Society for Endocrinology BES conference to take place in UK from 11-14 April 2011

PecFent accepted in Scotland for treatment of breakthrough cancer pain

Minimally invasive technique appears helpful in reanimating lower face after paralysis

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

New magnetic pill system can serve as drug delivery tool in patients with cancer, diabetes

12-HETE enzyme inhibition can prevent ischemic retinopathy: Study

Adjunctive lacosamide reduces seizures and improves responder rates

PPPI-III conference to focus on fundamental research and industrial application of particulate processing

Family physicians often uncomfortable in discussing IUDs with patients

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Patients prepared to travel 'dental miles' to register with NHS dentists

Apixaban drug raises hope for DVT prevention in patients undergoing hip replacement surgery

Eli Lilly, Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Rib-X raises $20M to support development of broad spectrum antibiotics pipeline

SciClone initiates phase 2b study of SCV-O7 for oral mucositis

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News